Elevance Health, Inc.
ELV
$300.74
+0.75%
Elevance Health, Inc. is a leading US health insurer operating in the Medical - Healthcare Plans industry. The company is defined by its unique position as the largest single provider of Blue Cross Blue Shield branded coverage and is expanding its reach in government-sponsored programs and healthcare services.…
ELV
Elevance Health, Inc.
$300.74
ELV 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Elevance Health, Inc.'s 12-month outlook, with a consensus price target around $390.96 and implied upside of +30.0% versus the current price.
Average Target
$390.96
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$241 - $391
Analyst target range
Wall Street analysts maintain a bullish consensus on Elevance Health, with recent ratings from major firms including 'Overweight' from Barclays, JP Morgan, and Wells Fargo, and 'Buy' from Truist Securities and Guggenheim. The most recent action was an 'Outperform' reiteration from Mizuho on March 11, 2026. While a specific consensus target price is not provided in the data, the unanimous positive bias among covering analysts suggests confidence in the company's long-term fundamentals despite recent stock price weakness. Analyst estimates for the upcoming period average an EPS of $46.13 and revenue of $229.5 billion.
ELV Technical Analysis
The stock has experienced significant volatility and a pronounced downtrend over the observed six-month period. The price fell from a high near $382 in mid-January 2026 to a low near $280 in early March, representing a decline of over 26%. The 1-month and 3-month price changes are -8.52% and -16.49%, respectively, significantly underperforming the S&P 500, which declined -5.25% and -4.63% over the same periods.
Short-term performance has been weak, with the stock price falling 8.52% over the past month. This decline follows a sharp drop on January 27, 2026, where the price fell from $376.93 to $322.92 in a single day, indicating a significant negative catalyst. The stock has struggled to recover from this event, trading in a lower range between roughly $280 and $295 for most of March.
The current price of $292.75 is positioned near the lower end of its 52-week range of $273.71 to $458.75, representing only about 10.3% above the 52-week low. This indicates the stock is in a deeply oversold position relative to its recent trading history. No RSI data was provided for further momentum analysis.
Beta
0.47
0.47x market volatility
Max Drawdown
-39.3%
Largest decline past year
52-Week Range
$274-$459
Price range past year
Annual Return
-30.0%
Cumulative gain past year
| Period | ELV Return | S&P 500 |
|---|---|---|
| 1m | +5.9% | -3.6% |
| 3m | -15.1% | -4.0% |
| 6m | -14.2% | -2.0% |
| 1y | -30.0% | +16.2% |
| ytd | -15.1% | -3.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ELV Fundamental Analysis
Revenue and profitability showed strength in the first three quarters of 2025 but weakened significantly in Q4. Quarterly revenue grew year-over-year by 9.47% in Q4 2025 to $49.75 billion. However, net income plummeted to $547 million in Q4 from $2.18 billion in Q1, with the net margin compressing to 1.10% from 4.47%. This suggests rising medical costs or other expenses pressured late-year results.
The company maintains a moderate debt-to-equity ratio of 0.76, indicating a manageable level of financial leverage. Free cash flow for the trailing twelve months is a healthy $3.17 billion, providing ample liquidity for dividends, buybacks, and investments. The current ratio of 1.24 suggests sufficient short-term assets to cover near-term liabilities.
Return on Equity (ROE) for the latest period stands at 12.90%, which is a respectable level of profitability generated from shareholder equity. The provided asset turnover data is not recent enough for a current operational efficiency analysis, but the stable ROE and strong market position suggest generally efficient operations.
Quarterly Revenue
$49.7B
2025-12
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.23%
Latest Quarter
Free Cash Flow
$3.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ELV Overvalued?
Given the company's positive net income, the primary valuation metric used is the Price-to-Earnings (P/E) ratio. The trailing P/E ratio is 13.73, while the forward P/E is 9.94 based on analyst estimates. This forward multiple suggests the market is pricing in significant earnings growth or views the stock as undervalued relative to near-term profit expectations.
Peer comparison data is not available in the provided inputs. Other valuation metrics include a Price-to-Sales (P/S) ratio of 0.39 and an Enterprise Value-to-Sales (EV/Sales) ratio of 0.31, both of which appear low and could indicate the market is assigning a discounted valuation to the company's revenue base, possibly due to margin concerns highlighted in the Q4 results.
PE
13.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 11x~50x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.5x
Enterprise Value Multiple